Janssen Pharmaceutica N.v.

SAN FRANCISCO, November 5, 2011 - Data presented at AASLD 2011 highlights efficacy in typically hard to treat patients NOT INTENDED FOR US JOURNALISTS Janssen Pharmaceutica NV (Janssen), today presented new data for INCIVO (telaprevir) at the American Association for the Society of Liver Disease (AASLD) Annual Meeting, highlighting the safety and efficacy of a telaprevir based regimen in cirrhotic patients who had previously failed treatment.

BEERSE, Belgium, December 1, 2010 - Janssen Pharmaceutica N.V., (Janssen) today announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer's disease prior to the onset of clinical symptoms.